Van MeursHS, TajikP, HofMH, et al.: Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer, 2013. E-pub ahead of print. DOI: 10.1016/j.ejca.2013.06.01.3.
2.
TangjitgamolS, ManusirivithayaS, LaopaiboonM, et al.: Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev, 2013; 4:CD00601.4.
3.
EitanR, KrissiH, LevaviH, et al.: Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention. PLoS One, 2013. E-pub ahead of print. DOI: 10.1371/journal.pone.0055645.
4.
FotopoulouC, ZangR, GultekinM, et al.: Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol, 2013; 20:1348–1354.
5.
HeitzF, du BoisA, KurzederC, et al.: Surgery for recurrent ovarian cancer. Womens Health (Lond Engl), 2011; 7:529–535.
